Atara Biotherapeutics Inc (NASDAQ:ATRA)
| 0.6956 Delayed Data As of Dec 07 |  +0.0357 / +5.41%Today’s Change | 0.20 Today|||52-Week Range 5.64 | -78.79% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $66.2M |
Company Description
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.
Contact Information
Atara Biotherapeutics, Inc. 2380 Conejo Spectrum Street Thousand Oaks California 91320 |
Employees
Shareholders
| Other institutional | 63.13% |
| Mutual fund holders | 35.73% |
| Individual stakeholders | 13.31% |
Top Executives
| Pascal Touchon | President, Chief Executive Officer & Director |
| Eric Hyllengren | Chief Financial & Accounting Officer |
| Manher AJ Joshi | Chief Medical Officer |
| Anhco Nguyen | Chief Scientific Officer |
| K. Amar Murugan | Chief Legal Officer, Senior VP & General Counsel |
